Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy
Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have a 5-year survival rate of less than 8%. In an attempt to improve this, epigenetic modifying agents have been combined as therapies in clinical studies. In particular combinations with Decitabine and V...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Published: |
Impact Journals
2017
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/49749/ |